Email
amanda.adler@drl.ox.ac.uk
Location
Oxford
United KingdomBio
The Diabetes Trials Unit is delighted to welcome Dr Amanda Adler as the incoming DTU Director, taking over from Professor Rury Holman in September 2019.
Dr Adler chairs a Technology Appraisal Committee with the National Institute for Health and Care Excellence (NICE), and also chaired their National Guidelines Committee for Newer Agents for Type 2 Diabetes and the Quality Standard for Diabetes for England.
Currently a consultant physician at the Institute of Metabolic Sciences at Addenbrooke's Hospital in Cambridge, Dr Adler practices diabetes and general medicine in the in-patient, out-patient and community settings. She worked previously with Professor Holman in Oxford as the Clinical Epidemiologist for the United Kingdom Prospective Diabetes study (UKPDS) and has been involved subsequently in helping to run a number of DTU trials, including the Treating To Target in Type 2 Diabetes (4-T) trial and the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).
Dr Adler is a Fellow of the Royal College of Physicians, and has helped the MHRA and EMA in issues related to the safety of drugs for diabetes.
Dr Adler chairs a Technology Appraisal Committee with the National Institute for Health and Care Excellence (NICE), and also chaired their National Guidelines Committee for Newer Agents for Type 2 Diabetes and the Quality Standard for Diabetes for England.
Currently a consultant physician at the Institute of Metabolic Sciences at Addenbrooke's Hospital in Cambridge, Dr Adler practices diabetes and general medicine in the in-patient, out-patient and community settings. She worked previously with Professor Holman in Oxford as the Clinical Epidemiologist for the United Kingdom Prospective Diabetes study (UKPDS) and has been involved subsequently in helping to run a number of DTU trials, including the Treating To Target in Type 2 Diabetes (4-T) trial and the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).
Dr Adler is a Fellow of the Royal College of Physicians, and has helped the MHRA and EMA in issues related to the safety of drugs for diabetes.